Background: Currently, there is no information on whether in-hospital heart rate (HR) reduction has an influence on risk of death or rehospitalization. The study evaluates the relation between inhospital HR reduction in heart failure (HF) patients on mortality and rehospitalization within 1-year observation. Methods: The analysis included patients hospitalized in Poland with sinus rhythm from the European Society of Cardiology Heart Failure Pilot (ESC-HF-Pilot) and ESC Heart Failure Long-Term Registries (ESC-HF-LT), who were divided into two groups: reduced HR and not-reduced HR. HR reduction was defined as a reduced value of HR at discharge compared to admission HR. The primary endpoint was 1-year all-cause death, the secondary endpoint was 1-year all-cause death or rehospitalization for worsening HF. Results: The final analysis included 747 patients; 491 reduced HR (65.7%) and 256 not-reduced HR (34.3%). The primary endpoint occurred in 58/476 (12.2%) from reduced HR group and in 26/246 (10.5%) from not-reduced HR group (p = 0.54). In the reduced HR group, independent predictors of primary endpoint were age, New York Heart Association class at admission, serum sodium level at admission and systolic blood pressure at discharge. In the not-reduced HR group the independent predictor of primary endpoint was diastolic blood pressure at discharge. The secondary endpoint was observed in 180 patients, 124/398 (31.2%) from reduced HR and 56/207 (27.1%) from the not-reduced HR group (p = 0.30). In the not-reduced HR group only angiotensin converting-enzyme inhibitor usage at discharge was independently associated with lower risk of the secondary endpoint. Conclusions: In-hospital HR reduction did not influence on the outcomes of HF patients in sinus rhythm. (Cardiol J 2020; 27, 1: 25-37) 
Introduction
Although the treatment of heart failure (HF) has been improving in recent decades, the outcome of HF patients is still not satisfactory [1, 2] . Increasing prevalence of HF in developing countries is a great challenge for contemporary cardiology. Proper identification of risk factors of death or rehospitalization is crucial for the management of HF patients.
The most comprehensive and reliable data concerning the risk factors and outcome of patients with HF come from international observation registries. The European Society of Cardiology (ESC) created the Heart Failure Pilot (ESC-HF-Pilot) and Heart Failure Long-Term (ESC-HF-LT) Registries to assess the clinical characteristics and outcome of HF patients in clinical practice in European countries. Recently published analyses of data from both Registries revealed several risk factors associated with 1-year outcomes in hospitalized HF patients [1, [3] [4] [5] [6] . One of the modifiable predictors of cardiovascular mortality and morbidity is heart rate (HR), which is associated with poor prognosis in general population, patients with hypertension, coronary artery disease and HF [2, [7] [8] [9] [10] [11] . Laskey et al. [12] reported, that higher HR at discharge in hospitalized HF patients significantly increased the risk of death or rehospitalization. However, there is still no information on whether in-hospital reduction of HR modifies risk of death or rehospitalization.
The aim of the current analysis was to evaluate the influence of in-hospital HR reduction in HF patients with sinus rhythm (SR) on mortality and/or rehospitalization over a 1-year observation period.
Methods

Study population
In the present analysis, data from two prospective, multicenter registries were included: ESC-HF-Pilot and ESC-HF-LT [1, 2, 13, 14] . The ESC-HF-Pilot Registry included data gathered between October 2009 and May 2010 in 136 European centers, including 29 centers localized in Poland. The ESC-HF-LT Registry consists of three phases, including data from 211 centers in 21 European countries. The I phase of the ESC-HF-LT Registry was conducted between May 2011 and April 2013 and enrolled patients 1 day per week for the whole year. Adult patients (at least 18 years old) with newly-diagnosed HF (using clinical, biochemical and echocardiographic findings) or worsening of HF were enrolled in the Registries. The ESC-HF-Pilot and ESC-HF-LT Registries recruited patients hospitalized for HF and outpatients seen in ambulatory care. Exclusion criteria were not specified. All patients signed an informed consent. The study was approved by the local Ethical Review Board.
In the current analysis only hospitalized patients enrolled in the ESC-HF-Pilot Registry and in phase I of the ESC-HF-LT Registry in SR were taken into account. Atrial fibrillation/atrial flutter and/or paced rhythm on 12-lead electrocardiogram (ECG), as well as lack of ECG recording during index hospitalization were excluded from the current analysis.
All data according to the medical history, concomitant diseases and clinical status at admission and hospital discharge were obtained. Follow-up of the patients lasted 1 year. During the follow-up data regarding all-cause death and readmission for HF worsening were collected.
Study groups
Patients were divided into two groups according to HR difference during index hospitalization from admission to discharge: with or without HR reduction. HR values were assessed during standard physical examination. HR reduction was defined as a reduced value of HR recorded at discharge in comparison to the value observed upon admission. Patients with HR reduction (reduced-HR group) and without HR reduction (not-reduced-HR group) during index hospitalization were compared in regard to demographics, medical history, clinical status and pharmacotherapy at the moment of admission, during index hospitalization and at hospital discharge.
Endpoints
In both Registries, the primary endpoint was 1-year all-cause death, whereas the secondary endpoint was composed of 1-year all-cause death or rehospitalization for worsening HF.
Statistical analysis
Normality of distribution of variables was assessed using the Shapiro-Wilk test. Continuous non-normally distributed variables were presented as median values and interquartile range (IQR). Categorical data were presented as percentage and absolute frequencies. Statistical significance of differences between groups was assessed: for quantitative variables with U Mann-Whitney test and for qualitative variables -with Fisher exact test. Cox proportional hazard regression models were used to determine predictors of the primary and secondary endpoints. Only variables with p < 0.1 in univariate analysis were included in multivariate analysis. A value of p < 0.05 was considered significant for all tests. Statistical analysis performed using SAS ® software, version 9.4.
Study group selection
Overall, in all European countries 5118 patients were enrolled in the ESC-HF-Pilot Registry and 12,440 patients in the ESC-HF-LT Registry. The Polish cohorts of the ESC-HF-Pilot and ESC-HF-LT Registries included 630 and 743 HF patients who were discharged after index hospitalization, respectively. Firstly, 139 patients were excluded from the current analysis, because of paced rhythm observed in ECG recording. Secondly, 460 patients with present atrial fibrillation/atrial flutter during index hospitalization were excluded from further analysis. Other rhythms or lack of ECG were noted in 27 patients. Finally, ECG recordings on admission and discharge were available for 747 (100%) patients. The flow chart of patient enrollment in the analysis is shown in Figure 1 . HR reduction was observed in 491 of 747 (65.7%) patients, while lack of HR reduction in 256/747 (34.3%) patients included in the study. Follow-up data was excluded for 25 patients, resulting from a lack of response after direct, investigator contact.
Results
Study group characteristics
Median age in the group analyzed was 67.0 (57.6-77.0) years, 68.5% of patients were male. Median HR value at admission in the total population was 80 (70-90) beats per minute (bpm). In the reduced HR group median HR at admission was 84 (75-100) bpm, whereas in the not-reduced HR group 70 (60-75) bpm (p < 0.0001). Furthermore, median HR value at discharge was 70 (64-78) bpm in the population analyzed, 70 (62-75) bpm in the reduced HR group and 72 (68-80) bpm in the notreduced HR group (p < 0.0001). Median value of HR reduction in the reduced HR group was 15 bpm (IQR: 8-25 bpm). The reduced HR group more frequently had hypertension (71.0% vs. 63.3%; p = 0.04) and less frequently used antiplatelets before the index hospitalization (58.2% vs. 69.4%; p = 0.003) in comparison to the not-reduced HR group. According to clinical status at admission, ; p = 0.0005) and more frequently were admitted because of acute coronary syndrome ([ACS] 27.5% vs. 20.7%; p = 0.04). Moreover, reduced HR group had a longer duration of index hospitalization (7 [4] [5] [6] [7] [8] [9] [10] [11] vs. 6 [3] [4] [5] [6] [7] [8] [9] ; p = 0.004), in comparison to the not-reduced HR group. A full comparison of both groups in regard to baseline characteristics, clinical course of index hospitalization, in-hospital and long-term outcomes are presented in Table 1 . As shown in Table 2 , HR at admission was significantly higher in the ESC-HF-Pilot Registry population in comparison to the group enrolled in the ESC-HF-LT Registry (80 [70-95] vs. 78 [68-90]; p = 0.02). The comparison between these two Registries did not show significant differences in regard to HR at discharge, mean HR reduction during hospitalization or the percentage of patients who achieved HR reduction ( Table 2) .
One-year outcomes
Moreover, no significant differences were observed between groups in occurrence of primary and secondary endpoints. In comparison of reduced HR and not-reduced HR groups, hazard ratios of prevalence of primary and secondary endpoints were 1.16 (95% confidence interval [CI] 0.73-1.84; p = 0.54) and 1.15 (95% CI 0.85-1.56; p = 0.38), respectively. Kaplan-Meier curves present outcomes of reduced HR and not-reduced HR groups are shown in Figure 2 .
Primary endpoint
In the population analyzed, 722 patients completed 1-year follow-up and primary endpoint occurred in 84/722 patients (11.6%). In the reduced HR group, primary endpoint was observed more frequently (58/476, 12.2%), than in the not-reduced HR group (26/246, 10.5%; p = 0.54). Tables 3  and 4 present risk factors for 1-year all-cause death in univariate analysis in the reduced HR and not-reduced HR groups, respectively. In the multivariate analysis only older age, higher NYHA class at admission, lower serum sodium at admission and lower SBP at discharge were revealed to be independent predictors of primary endpoint in the reduced HR group (Table 5 ). In multivariate analysis only lower DBP at discharge remained to be a statistically significant predictor of 1-year all-cause death in the not-reduced HR group, as shown in Table 6 .
Secondary endpoint
In the total population, data on 1-year followup were available for 605 patients. In the whole analyzed group, secondary endpoint was observed in 180 (29.8%) patients, 124/398 (31.2%) from the reduced HR and 56/207 (27.1%) from the not-reduced HR group (p = 0.30). Tables 3 and 4 present risk factors for secondary endpoint in univariate analysis in the reduced HR and not-reduced HR groups, respectively. In the reduced HR group, the multivariate analysis did reveal these factors to reach statistical significance (Table 5 ). However, there were trends for diabetes, history of stroke, higher NYHA class at admission and lower serum sodium at admission towards independent prediction of secondary endpoint in the reduced HR group. In the not-reduced HR only the use of angiotensin converting enzyme inhibitor at discharge was independently associated with lower risk of all-cause death or rehospitalization for worsening HF, as presented in Table 6 .
Discussion
The current study has revealed that HR reduction during the hospitalization for HF was not associated with benefits in patients with SR. Moreover, predictors of all-cause death or combined endpoint (death or rehospitalization for worsening HF) at 1 year were partly comparable in patents with and without HR reduction during index hospitalization.
Among numerous demographic and clinical factors, only a few of them differed between patients with and without in-hospital HR reduction. In the reduced-HR group higher NYHA class was observed. Not much is known about the correlation between NYHA class and HR at hospital admission. However, Ahmed et al. [15] revealed no significant differences in HR at admission and NYHA class I-II vs. III-IV in patients with HF with preserved function of the left ventricle. Moreover, results from the current analysis showed that in the reduced HR group, higher NYHA class at admission is significantly related to all-cause death at 1 year. These findings are consistent with results of previous analyses performed in hospitalized HF patients enrolled in the ESC-HF-Pilot and ESC-HF-LT Registries [1, 3, 4] .
In the present analysis, the reduced HR group less frequently used beta-blockers (BBs) prior to 7 (4-10); n = 722 6 (3-9); n = 246 7 (4-11); n = 476 0.004
One-year outcome
One Bolded values indicate p-values < 0.05. ACEI -angiotensin converting enzyme inhibitor; ACS -acute coronary syndrome; ARB -angiotensin receptor blocker; BMI -body mass index; CABG -coronary artery bypass grafting; COPD -chronic obstructive pulmonary disease; DBP -diastolic blood pressure; HF -heart failure; HR -heart rate; LVEF -left ventricular ejection fraction; NYHA -New York Heart Association; PCI -percutaneous coronary intervention; SBP -systolic blood pressure Additionally, in the HR reduction group a higher percentage of patients presented with ACS as a cause of admission. Myftiu et al. [16] reported that, in patients presenting with acute myocardial infarction (AMI) the group with HF upon admission had significantly higher HR at admission in comparison to the AMI without HF group. Moreover, myocardial infarction may be a reason for BB implementation, which contributes to a reduction of HR.
Several recent clinical trials and populationbased studies reported significant associations between HR and outcomes in patients with HF. Previous analysis of the ESC-HF Pilot Registry showed that higher HR at admission was associated with worse clinical course during index hospitalization [5] . The placebo-subgroup analysis of patients with stable coronary artery disease and left-ventricular dysfunction enrolled in the BEAU-TIFUL (morBidity -mortality EvAlUaTion of the 
Product-limit survival estimates
With number of subject at risk and 95% condence limits
With number of subject at risk and 95% condence limits Bolded values indicate p-values < 0.05. ACEI -angiotensin converting enzyme inhibitor; ACS -acute coronary syndrome; ARB -angiotensin receptor blocker; BMI -body mass index; CABG -coronary artery bypass grafting; CI -confidence interval; COPD -chronic obstructive pulmonary disease; DBP -diastolic blood pressure; LVEF -left ventricular ejection fraction; NYHA -New York Heart Association; PCI -percutaneous coronary intervention; SBP -systolic blood pressure; VF -ventricular fibrillation; VT -ventricular tachycardia Bolded text indicates p-values < 0.05. ACEI -angiotensin converting enzyme inhibitor; BMI -body mass index; CI -confidence interval; DBP -diastolic blood pressure; HR -hazard ratio; LVEF -left ventricular ejection fraction; NYHA -New York Heart Association; SBP -systolic blood pressure In the present analysis, differences in usage of BB were observed. Compared with the not-reduced HR group, in the HR reduced group fewer patients used BBs before admission and more of them used BBs at discharge from the hospital. However, these discrepancies did not reach statistical significance.
Conclusions
The current study evaluates the impact of in-hospital HR reduction during hospitalization in HF patients on 1-year mortality and rehospitalization. The results of the present study revealed that HR reduction during hospitalization for HF is not associated with outcome of patients with SR. Moreover, predictors of primary endpoint and secondary endpoint were similar in patients with and without HR reduction during index hospitalization.
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